Humaid Al-Shamsi, Chairman at Nexomic, CEO of Burjeel Cancer Institute, and President of the Emirates Oncology Society, shared on LinkedIn:
“Nexomic is pleased to welcome Dr. Paolo Tarantino from Dana-Farber Cancer Institute and Harvard University to its Expert and growing world class Advisory Board.
His internationally recognised expertise in antibody – drug conjugates (ADCs) in breast cancer will further strengthen Nexomic’s research in precision oncology.
Biomarker development, treatment-response prediction, and the clinical translation of next-generation ADC strategies across breast cancer and other solid tumors. ”
